Key Highlights
- Merck (NYSE:MRK) presented one-year data on October 12, 2026 for remigromig in diabetic macular edema, with vision gains of 9.1 and 8.7 letters in two arms versus 11.8 letters for ranibizumab.
- Proliferative diabetic retinopathy, an advanced and sight-threatening stage of the disease, appeared in 6.7% and 6.1% of remigromig patients versus 0.9% on ranibizumab, a safety signal that investors will watch.
- The numbers come from company data, and Merck (NYSE:MRK) shares were about flat in premarket trading, so the market did not treat the result as a major surprise either way.
- Gains are measured in letters read on an eye chart, and a lower number than the comparator suggests the new drug did not match the standard in this analysis.
The Data Presented
Merck (NYSE:MRK) presented one-year results on October 12, 2026 for remigromig, its candidate for diabetic macular edema, a swelling of the central retina caused by leaking blood vessels in people with diabetes. Vision improved by 9.1 letters and 8.7 letters in the two remigromig groups, compared with 11.8 letters for ranibizumab, an established injection that blocks vascular endothelial growth factor. Each letter is a line read on an eye chart, so a gap of about 2.7 to 3.1 letters is simple arithmetic on those published numbers. The numbers are verified as company data, though the trial design, size and statistical analysis were not captured in published information.
The Safety Signal
The more notable figure is the rate of proliferative diabetic retinopathy, the stage in which abnormal new vessels grow on the retina and can cause bleeding or detachment. It appeared in 6.7% and 6.1% of patients on remigromig versus 0.9% on ranibizumab. Anti-VEGF drugs like ranibizumab can slow disease progression, so a higher rate with a new mechanism raises the question of whether remigromig controls the underlying disease as well. Published information does not say how the events were defined, how many patients were involved or whether the difference was statistically tested, and the numbers should be read together with full results. Ranibizumab is injected into the eye and has been used for diabetic eye disease for years, so it is a demanding comparator for any newcomer.
Risks and What to Watch
For Merck (NYSE:MRK), a large company with many products, a single eye program is unlikely to define the share price, which is consistent with the flat premarket quote. Investors can watch for details on trial design, the regulatory plan and whether Merck (NYSE:MRK) proceeds to later-stage studies. Risks include slower recruitment, tougher safety review and competition from established injections. Patients and doctors also value fewer injections, a benefit not shown here. A weaker efficacy number does not end a program, but it raises the bar for the next trial. This article is not medical or investment advice. The dosing schedule and the number of injections were not captured, though fewer injections could matter to patients.
Where Things Stand
Remigromig did not match ranibizumab on vision gain in this one-year company data, with 9.1 and 8.7 letters against 11.8, and it showed more proliferative diabetic retinopathy at 6.7% and 6.1% against 0.9%. Merck (NYSE:MRK) shares were about flat premarket, which suggests limited impact, and the full dataset will decide how the program is judged. The data show a gap in both vision gain and in disease progression, and Merck (NYSE:MRK) must now show doctors why the new approach is worth using, perhaps through convenience or different biology.






Please wait processing your request...